Dr. Federico Monzon is a Physician Executive with a broad background in clinical genomics and molecular diagnostics both in the academic and industry settings. Federico is a molecular genetics pathologist with a strong track record of innovation in the clinical laboratory through development and translation of novel genomic technologies to the clinic, including leading studies on tumors of unknown origin, prostate, renal and skin cancer genomics.
Federico is a currently an independent consultant, supporting innovative diagnostic and biotechnology companies with medical/scientific leadership to support test development and commercialization efforts. Prior to consulting, we was Chief Medical Officer at Castle Biosciences, a laboratory focused on providing genomic prognostic tools to patients with melanoma and other skin cancers. In this role, he oversaw the R&D and Medical Affairs departments as well as supported their reimbursement efforts to help Castle achieve a successful IPO in July 2019. Before that, he served as Medical Director of Oncology and Medical Director for Latin America at Invitae, a provider of genetic diagnostics for hereditary disorders. Previously, he served as Director of Pathology at the Cancer Genetics Laboratory from Baylor College of Medicine.
Federico earned his M.D. from the Universidad Nacional Autónoma de México and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. He was the 2017 President of the Association for Molecular Pathology (AMP) and continues to be engaged in AMP and other professional societies to shape the future of clinical genomic medicine.